Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

le vet beheer b. v. - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 50.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 12.5 mg/tb - antibiotic & related - dog - small or toy | dog - small | dog - toy - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

le vet beheer b. v. - amoxycillin (as the trihydrate); clavulanic acid as potassium clavulanate - oral tablet - amoxycillin (as the trihydrate) antibiotic active 250.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 62.5 mg/tb - antibiotic & related - dog - medium | castrate - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 250 mg - levetiracetam tablets, usp are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. information describing the use of levetiracetam in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for ucb, inc.’s levetiracetam tablets and oral solution. however, due to ucb inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. levetiracetam tablets, usp are indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam tablets, usp are indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.      none. levetiracetam levels may decrease during pregnancy [see warnings and precautions (5.9)]. preg

United States - English - NLM (National Library of Medicine)

methapharm, inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 250 mg - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam tablets or oral solution. the abuse and dependence potential of levetiracetam has not been evaluated in human studies.

United States - English - NLM (National Library of Medicine)

llc federal solutions - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 100 mg in 1 ml - indication and usage levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. contraindications this product should not be administered to patients who have previously exhibited hypersensitivity to levetiracetam or any of the inactive ingredients in levetiracetam oral solution. drug abuse and dependence the abuse and dependence potential of levetiracetam has not been evaluated in human studies.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

le vet beheer b. v. - amoxycillin (as the trihydrate); clavulanic acid as potassium clavulanate - oral tablet - amoxycillin (as the trihydrate) antibiotic active 500.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 125.0 mg/tb - antibiotic & related - dog - large - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Austria - English - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril

Spain - English - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril

France - English - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril

Italy - English - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril